257 related articles for article (PubMed ID: 23383079)
1. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
Liu HB; Wu Y; Lv TF; Yao YW; Xiao YY; Yuan DM; Song Y
PLoS One; 2013; 8(1):e55128. PubMed ID: 23383079
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
Asian Pac J Cancer Prev; 2012; 13(10):5177-82. PubMed ID: 23244131
[TBL] [Abstract][Full Text] [Related]
3. A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Zaborowska-Szmit M; Kowalski DM; Piórek A; Krzakowski M; Szmit S
Pharmacol Rep; 2016 Dec; 68(6):1140-1148. PubMed ID: 27588390
[TBL] [Abstract][Full Text] [Related]
4. Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis.
Wang H; Huang J; Yu X; Han S; Yan X; Sun S; Zhu X
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1901-9. PubMed ID: 24908327
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis.
Chen Y; Wen S; Wu Y; Shi L; Xu X; Shen B
Crit Rev Oncol Hematol; 2021 Jul; 163():103393. PubMed ID: 34119658
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
Yan H; Li H; Li Q; Zhao P; Wang W; Cao B
PLoS One; 2015; 10(8):e0135829. PubMed ID: 26285137
[TBL] [Abstract][Full Text] [Related]
7. Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis.
Xu C; Zhou Q; Wu YL
J Hematol Oncol; 2012 Oct; 5():62. PubMed ID: 23050865
[TBL] [Abstract][Full Text] [Related]
8. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.
Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
Lung Cancer; 2012 Oct; 78(1):8-15. PubMed ID: 22795701
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
11. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
14. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis.
Jiang T; Min W; Li Y; Yue Z; Wu C; Zhou C
Cancer Med; 2016 Jun; 5(6):1055-65. PubMed ID: 26990668
[TBL] [Abstract][Full Text] [Related]
16. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
An N; Zhang Y; Niu H; Li Z; Cai J; Zhao Q; Li Q
Medicine (Baltimore); 2016 Dec; 95(50):e5601. PubMed ID: 27977598
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of EGFR-TKIs for non-small cell lung cancer: A meta-analysis of randomized controlled clinical trials.
Lai X; Zeng J; Xiao Z; Xiao J
Medicine (Baltimore); 2024 Jun; 103(23):e38277. PubMed ID: 38847673
[TBL] [Abstract][Full Text] [Related]
18. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Liu ZL; Zhu WR; Zhou WC; Ying HF; Zheng L; Guo YB; Chen JX; Shen XH
J Integr Med; 2014 Jul; 12(4):346-58. PubMed ID: 25074884
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis.
Lee HJ; Jeong GH; Li H; Kim MS; Kim JS; Park SJ; Han YJ; Lee KH; Kronbichler A; Hong SH; Ghayda RA; Luchini C; Nottegar A; Koyanagi A; Smith L; Jacob L; Dragioti E; Radua J; Cargnin S; Terrazzino S; Thompson T; Yon DK; Lee SW; Yang JM; Wasuwanich P; Shin JI; Gamerith G
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6232-6244. PubMed ID: 34730203
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
